Register for our free email digests:
Latest From Anadys Pharmaceuticals Inc.
Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.
Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.
San Diego-based eFFECTOR Therapeutics has raised $45 million in Series A venture capital to develop small molecules that selectively regulate protein synthesis – otherwise known as translation – and advance a cancer drug candidate into human trials within three years.
Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos
Regulus notched two partnerships and an IPO in 2012, putting it on firmer financial ground. Now, as it transitions to executing on its partnerships and pushing ahead with its internal programs, its task is to demonstrate the clinical utility of its miRNA compounds.
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- Alcobra Ltd.
- Senior Management
Tomer Berkovitz, PhD, CFO
Jonathan Rubin, MD, CMO
David C Baker, Chief Commercial Officer
- Contact Info
Phone: 72-220 4661
132 Derech Menachem Begin
Tel Aviv, 6701101
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.